# Regeneron Pharmaceuticals, Inc. (REGN) — Q4-2013 Earnings Results

**Report date:** 2014-02-11 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q4-2013

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 7.41%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.24 | N/A | +121.13% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Confident

Management expressed confidence in the company's performance despite not providing specific revenue figures. They emphasized their commitment to innovation.

**Key quotes:**

> The company is pleased with the strong EPS performance this quarter.

> We continue to focus on innovation and growth in our pipeline.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's strong EPS performance significantly exceeded expectations, leading to a 7.41% increase in stock price. The positive reaction reflects investor confidence in the company's ongoing strategies and potential for future growth, despite the lack of revenue data and guidance.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q4-2013_